FH-2001 / Fosun Pharma - LARVOL DELTA

FH-2001 is a novel FGFR/VEGFR dual inhibitor with immune-modulating activity. (PubMed, Anticancer Drugs) - "Mechanistically, FH-2001 treatment dramatically reduced c-Myc and PD-L1 mRNA and protein levels in a dose-dependent manner in vitro. Taken together, FH-2001 is a promising dual-target inhibitor of FGFR and VEGFR and also modulates cancer immunity, while its robust antitumor activity positions it as a potentially class-leading anticancer agent."

IO biomarker • Journal • Oncology • Solid Tumor • FGFR • FLT1 • MYC

A multicenter, open-label, two-cohort, single-arm Phase Ib/II clinical study to evaluate the safety and preliminary efficacy of FH-2001 in combination with Serplulimab in subjects with advanced solid tumors (ChiCTR) - P2 | N=144 | Not yet recruiting | Sponsor: Zhongshan Hospital; Jiangsu Xingsheng Xinhui Pharmaceutical Co., LTD

Combination therapy • Metastases • New P2 trial • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor